ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models.
Hiroyasu KonnoTracey LinRenyi WuXinchuan DaiShou LiGrace WangMin ChenWenying LiLina WangBee-Chun SunZhen LuoTom HuangYuping ChenJohn ZhangQiuping YeDavid BellovinBing WanLishan KangChristopher SzetoKarl HsuOmar KabbarahPublished in: Cancer research communications (2022)
ZL-1211, anti-CLDN18.2 therapeutic antibody can target CLDN18.2-high as well as -low gastric cancers that may not be eligible for treatment with clinical benchmark. ZL-1211 treatment induces NK-cell activation with robust inflammation to further activate antitumor immunity in tumor microenvironment.